Drug intelligence / Profile preview

conantokin-t

Development stage
Discontinued
Modality
Peptides
Administration
Intrathecal, Central (experimental, In Animal Studies)
01

Overview

**Conantokin-t** is a 21-amino acid peptide isolated from the venom of the fish-hunting cone snail, *Conus tulipa*. It is part of the conantokin family, characterized by a high content of gamma-carboxyglutamate (Gla) residues. Conantokin-t acts as a potent antagonist of the N-methyl-D-aspartate receptor (NMDAR), inhibiting receptor-mediated calcium influx in central nervous system (CNS) neurons. Mechanistically, it nonselectively antagonizes multiple NMDAR subunits (notably both NR2A/GRIN2A and NR2B/GRIN2B), modulating excitatory synaptic transmission via interaction with glutamate and polyamine recognition sites on the receptor[1][2][3][5][9][10]. Its peptide structure adopts an alpha-helical conformation even in aqueous solutions[6][7]. Conantokin-t, along with other conantokins, has been explored at the preclinical and early clinical stages for potential use as a neuroprotective and analgesic agent, but no approved clinical applications exist and development has been discontinued for human use due to multiple challenges in clinical translation[4].

Other names
Con-T
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on conantokin-t.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on conantokin-t.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call